GlassScriptPhysician profile
Howard Rosenfeld
NPI 1639140486
$8,794.97
in general payments reported to CMS, 2019-2025
31 companies · $917 in 2025
The $917 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $1,120 · 2021: $1,782 · 2022: $1,374 · 2023: $1,297 · 2024: $1,079 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,723.09 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,479.48 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $842.74 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $832.75 | 2020-2025 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $721.03 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Novo Nordisk INC | $685.78 | 2019-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $353.32 | 2019-2024 | Cycloset |
| Amgen INC. | $262.89 | 2023-2025 | Repatha, Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $258.12 | 2021 | |
| Amarin Pharma, INC. | $206.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $200.64 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Allergan, INC. | $198.73 | 2019-2020 | |
| Pfizer INC. | $143.76 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $141.28 | 2019-2022 | |
| Exact Sciences Corporation | $117.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $108.10 | 2021-2023 | Xarelto |
| Amneal Pharmaceuticals LLC | $100.18 | 2022-2023 | Unithroid |
| Avvisto Therapeutics, LLC | $63.33 | 2024 | Cycloset |
| Abbott Laboratories | $46.34 | 2021-2022 | |
| Qol Medical, LLC | $45.50 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $44.77 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $36.92 | 2024 | Ryaltris |
| Bayer Healthcare Pharmaceuticals INC. | $35.32 | 2022 | |
| Esperion Therapeutics, INC. | $33.99 | 2021 | |
| Intra-Sana Laboratories | $18.91 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Shield Therapeutics INC | $18.31 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.14 | 2019 | |
| Phadia US INC. | $16.37 | 2025 | Immunocap |
| Sanofi Pasteur INC. | $14.67 | 2019 | |
| Circassia INC. | $14.64 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Rosenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.